Literature DB >> 17344359

Posaconazole treatment for Apophysomyces elegans rhino-orbital zygomycosis following trauma for a male with well-controlled diabetes.

T D Ferguson1, S D Schniederjan, J Dionne-Odom, M E Brandt, M G Rinaldi, F S Nolte, A Langston, S M Zimmer.   

Abstract

We report a case of rhino-orbital zygomycosis in a 43-year-old male with well-controlled diabetes mellitus. The patient initially received liposomal amphotericin B, but the infection continued to progress, so posaconazole treatment was begun and eventually led to the cure of his infection. The causative agent was identified as Apophysomyces elegans, an emerging cause of zygomycosis in immunocompetent hosts.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17344359      PMCID： PMC1865874          DOI： 10.1128/JCM.00014-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  Rhino-orbitocerebral mucormycosis attributable to Apophysomyces elegans in an immunocompetent individual: case report and review of the literature.

Authors:  L Garcia-Covarrubias; R Bartlett; D M Barratt; R J Wassermann
Journal:  J Trauma       Date:  2001-02

2.  Apophysomyces elegans as an agent of zygomycosis in a patient following trauma.

Authors:  K E Huffnagle; P M Southern; L T Byrd; R M Gander
Journal:  J Med Vet Mycol       Date:  1992

Review 3.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

4.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

Review 5.  Zygomycosis: the re-emerging fungal infection.

Authors:  M Chayakulkeeree; M A Ghannoum; J R Perfect
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

Review 6.  Posaconazole: a broad-spectrum triazole antifungal.

Authors:  Harrys A Torres; Ray Y Hachem; Roy F Chemaly; Dimitrios P Kontoyiannis; Issam I Raad
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

7.  Simple method of inducing sporulation by Apophysomyces elegans and Saksenaea vasiformis.

Authors:  A A Padhye; L Ajello
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

8.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Authors:  Jo-Anne H van Burik; Roberta S Hare; Howard F Solomon; Michael L Corrado; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-02-21       Impact factor: 9.079

Review 9.  Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans.

Authors:  Kimberly P Liang; Imad M Tleyjeh; Walter R Wilson; Glenn D Roberts; Zelalem Temesgen
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 10.  Invasive infection due to Apophysomyces elegans in immunocompetent hosts.

Authors:  W G Weinberg; B H Wade; G Cierny; D Stacy; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079
View more
  6 in total

1.  Invasive Apophysomyces variabilis infection in a burn patient.

Authors:  Wilfred P dela Cruz; Tatjana P Calvano; Matthew E Griffith; Christopher E White; Seung H Kim; Deanna A Sutton; Elizabeth H Thompson; Jianmin Fu; Brian L Wickes; Josep Guarro; Duane R Hospenthal
Journal:  J Clin Microbiol       Date:  2012-05-23       Impact factor: 5.948

Review 2.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

3.  Primary cutaneous mucormycosis produced by the new species Apophysomyces mexicanus.

Authors:  Alexandro Bonifaz; Alberto M Stchigel; Josep Guarro; Esther Guevara; Liliana Pintos; Marta Sanchis; José F Cano-Lira
Journal:  J Clin Microbiol       Date:  2014-10-08       Impact factor: 5.948

4.  Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern.

Authors:  A Chakrabarti; M R Shivaprakash; I Curfs-Breuker; A Baghela; C H Klaassen; J F Meis
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

5.  Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole.

Authors:  Zia U Khan; Suhail Ahmad; Arnost Brazda; Rachel Chandy
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

6.  Rhino-orbital-cerebral mucormycosis and aspergillosis: differential diagnosis and treatment.

Authors:  Susan Arndt; Antje Aschendorff; Matthias Echternach; Tanja Daniela Daemmrich; Wolfgang Maier
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-05-10       Impact factor: 2.503
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.